23andMe Holding Co. Updates earning guidance for 2022. The company previous full-year FY2022 guidance, excluding the effects of the Lemonaid Health acquisition, is unchanged. Updated FY2022 guidance, including the effects of the Lemonaid Health acquisition, will be provided with third quarter update. For purposes of net loss guidance, due to the unpredictable nature of market-driven changes, the company have assumed no net change in the fair value of warrant liability for the year.